Literature DB >> 6118346

Human ciliary process adrenergic receptor: pharmacological characterization.

J A Nathanson.   

Abstract

To better understand the nature of interaction of various amines with adrenergic receptors in te human ciliary process, beta-adrenergic-stimulated adenylate cyclase activity was characterized in broken cell preparations of this tissue from donor eyes. Among various agonists, isoproterenol was the most potent activator of enzyme activity (Ka = 3.4 x 10(-7)M), followed in order by epinephrine (Ka = 2.7 x 10(-6)M), norepinephrine (Ka = 2.1 x 10(-5)M), and phenylephrine (Ka greater than 10(-4)M). Isoproterenol-stimulated enzyme activity was blocked by timolol (Ki = 3.4 x 10(-9)M), IPS 339 (Ki = 4.4 x 10(-9)M), H35/25 (Ki = 6.9 x 10(-7)M), and atenolol (Ki = 1.4 x 10(-5)M). These pharmacological characteristics indicate that the human ciliary processes contain a predominance of beta2-adrenergic receptors. The findings are relevant to physiological studies of aqueous humor secretion and to the potential development of adrenergic agents with greater specificity for the beta-adrenergic receptor.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6118346

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  12 in total

Review 1.  Small-interfering RNAs (siRNAs) as a promising tool for ocular therapy.

Authors:  A Guzman-Aranguez; P Loma; J Pintor
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Binding potencies of 3 new beta 2 specific blockers to beta receptors in the ciliary processes and the possible relevance of these drugs to intraocular pressure control.

Authors:  G E Trope; B Clark
Journal:  Br J Ophthalmol       Date:  1984-04       Impact factor: 4.638

3.  beta-Adrenergic receptor subtypes and intraocular pressure.

Authors:  A Rushton
Journal:  Br J Ophthalmol       Date:  1983-08       Impact factor: 4.638

4.  Beta adrenergic receptors in pigmented ciliary processes.

Authors:  G E Trope; B Clark
Journal:  Br J Ophthalmol       Date:  1982-12       Impact factor: 4.638

5.  Sympathetic denervation hypersensitivity of the iris in ocular hypertension.

Authors:  C V Clark
Journal:  Doc Ophthalmol       Date:  1989-11       Impact factor: 2.379

Review 6.  Ophthalmic drug discovery: novel targets and mechanisms for retinal diseases and glaucoma.

Authors:  Kang Zhang; Liangfang Zhang; Robert N Weinreb
Journal:  Nat Rev Drug Discov       Date:  2012-06-15       Impact factor: 84.694

7.  Levobetaxolol hydrochloride: a review of its pharmacology and use in the treatment of chronic open-angle glaucoma and ocular hypertension.

Authors:  Luciano Quaranta; Raffaele Turano; Teodoro Pizzolante
Journal:  Clin Ophthalmol       Date:  2007-06

8.  Effects of adrenergic drugs on aqueous humour dynamics in the normal human eye. I. Salbutamol.

Authors:  R L Coakes; P B Siah
Journal:  Br J Ophthalmol       Date:  1984-06       Impact factor: 4.638

9.  ICI 118,551: an effective ocular hypotensive agent with selectivity for the ciliary process beta 2-adrenoceptor and with minimal cardiac side effects.

Authors:  J A Nathanson
Journal:  Br J Pharmacol       Date:  1984-11       Impact factor: 8.739

Review 10.  A major pathway for the regulation of intraocular pressure.

Authors:  M Sears; A Mead
Journal:  Int Ophthalmol       Date:  1983-06       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.